<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04444583</url>
  </required_header>
  <id_info>
    <org_study_id>REFLECS-FI</org_study_id>
    <nct_id>NCT04444583</nct_id>
  </id_info>
  <brief_title>Recognition of Heart Failure With Micro Electro-Mechanical Sensors (REFLECS) FI</brief_title>
  <acronym>REFLECS-FI</acronym>
  <official_title>Recognition of Heart Failure With Micro Electro-Mechanical Sensors (REFLECS) FI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Precordior Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Precordior Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart Failure (HF) is a condition where heart is unable to maintain adequate volume of blood
      in circulation corresponding to prevailing physiological demand. Gyrocardiography is a
      technique that utilizes micro electromechanical sensors (MEMS), accelerometer and gyroscope,
      to detect vibrations and rotation of thorax caused by cardiac motion. The main purpose of
      this study is to test the ability of an app of a smartphone with embedded motion sensors,
      positioned on the chest which measures the movements and function of the heart, to identify
      patients with different types of heart failure and their characteristics, as compared with
      clinical diagnosis. Echocardiography will also be used to confirm changes in cardiac cardiac
      mechanics including strain, cardiac torsion, diastolic filling characteristics.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HF specific motion sensor characteristics validation against echocardiography</measure>
    <time_frame>Baseline to Day 2</time_frame>
    <description>The study aims to validate HF specific characteristics obtained with accelerometer (m/s2) and gyroscope (degree/s) against the current gold standard, detailed echocardiography examination in individuals already diagnosed with HF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HF decompensation specific motion sensor characteristics validation</measure>
    <time_frame>14 weeks</time_frame>
    <description>The ability of the motion sensors to detect differences in myocardial mechanics in patients with decompensation episode compared to patients without decompensation episode, assessed by ROC.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Heart Failure</condition>
  <condition>Heart Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>HFpEF</arm_group_label>
    <description>HF patients with preserved ejection fraction (HFpEF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFrEF</arm_group_label>
    <description>HF patients with reduced ejection fraction (HFrEF)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients visiting Turku University Hospital Heart Center or Heart and Lung Center at
        Helsinki University Hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Patients visiting hospital for heart failure, either outpatient clinic or cardiac ward

          -  Signed informed consent as an acceptance to participate to the trial

        Exclusion Criteria:

          -  Age &lt;18 years

               -  Severe cardiac valve disease

               -  Previous prosthetic cardiac valve

               -  Major adverse cardiovascular event or surgery within 6 weeks of planned study
                  enrollment

               -  Patients with pacemaker

               -  Informed consent form not signed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>CEO, MD,PhD</last_name>
    <phone>(0)102021200</phone>
    <phone_ext>+358</phone_ext>
    <email>info@precordior.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Heart and Lung Center at Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riina Kandolin, MD,PhD</last_name>
      <phone>09-4711</phone>
      <phone_ext>+358</phone_ext>
      <email>riina.kandolin@hus.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heart Center at Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antti Saraste, MD,PhD</last_name>
      <phone>02- 313 0083</phone>
      <phone_ext>+358</phone_ext>
      <email>antti.saraste@tyks.fi</email>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 17, 2020</study_first_submitted>
  <study_first_submitted_qc>June 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

